<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39355453</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Evaluating Personalized Add-On Ayurveda Therapy in Oxygen-Dependent Diabetic COVID-19 Patients: A 60-Day Study of Symptoms, Inflammation, and Radiological Changes.</ArticleTitle><Pagination><StartPage>e68392</StartPage><MedlinePgn>e68392</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e68392</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.68392</ELocationID><Abstract><AbstractText>Background Effective management of both acute and post-acute sequelae of SARS-CoV-2 is essential, particularly for type 2 diabetes mellitus (T2DM) patients, who are at increased risk of severe pro-inflammatory responses and complications. Persistent symptoms and residual lung and cardiovascular damage in post-coronavirus disease (COVID-19) individuals highlight the need for comprehensive long-term treatment strategies. Conventional treatments, including Remdesivir and glucocorticoids, have limitations, suggesting that further investigation into Ayurvedic therapies could be beneficial, though controlled trials are currently limited. Objectives Evaluate the effectiveness and safety of Ayurveda with the standard of care (SOC) versus SOC in improving symptoms, moderating immune responses (interleukin-6 (IL-6), C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), and radiological outcomes in oxygen-dependent, high-risk, non-vaccinated type 2 diabetes COVID-19 patients over 60 days, and thus addressing their heightened vulnerability to severe infections. Methods A controlled trial with 50 diabetic COVID-19 patients, aged 18-80, with an NLR of &gt;= 4, primarily on Remdesivir, was assigned to Group 1 (Add-on Ayurveda+SOC, n=30) or Group 2 (SOC, n=20) based on their voluntary choice with follow-up on days 14, 28, and 60. Parametric outcomes in group analysis were assessed with robust regression and non-parametric outcomes with Cochran-Mantel-Haenszel, log-rank test, and chi-square tests at 95% confidence interval (CI). Results Group 1 exhibited statistically significant improvements in fever, cough, diarrhea, as well as NLR, IL-6, and CRP by 14 days, and in anosmia, loss of taste, shortness of breath, general weakness, and headache by 60 days. Though the sample size is small, notable improvements can be seen in troponin levels in Group 1 at 28 and 60 days. High-resolution computer tomography COVID-19 reporting and data system (HRCT CO-RADS) scores improved more slowly in Group 2 than in Group 1. Survival rates were 96.4% for Group 1 and 90% for Group 2. Numbers were too small for reliable comparisons at 60 days.  Conclusion The add-on Ayurveda group showed a better symptomatic response, and faster normalization in inflammatory markers, including IL-6 and NLR by 14 days, and cardiac markers by 28 days. Minimal clinical and no laboratory adverse events were observed. This study supports the need for a randomized, double-blind trial.</AbstractText><CopyrightInformation>Copyright © 2024, Kumar et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Somit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research, AVP Research Foundation, Coimbatore, IND.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development, The Arya Vaidya Pharmacy, Coimbatore, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramaraju</LastName><ForeName>Karthikeyan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakarla</LastName><ForeName>Mitravinda S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Statistics, AVP Research Foundation, Coimbatore, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eranezhath</LastName><ForeName>Sujith S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Basic and Translational Research, AVP Research Foundation, Coimbatore, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chenthamarakshan</LastName><ForeName>Chaithanya</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ayurveda and Integrative Medicine, AVP Research Foundation, Coimbatore, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alagesan</LastName><ForeName>Murali</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satheesan</LastName><ForeName>Balagopal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Ayurveda and Integrative Medicine, Saranya Ayurveda Hospital, Coimbatore, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unniappan</LastName><ForeName>Indulal</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Ayurveda and Integrative Medicine, AVP Research Foundation, Coimbatore, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilhalme</LastName><ForeName>Holly</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Statistics, University of California Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pīrāgs</LastName><ForeName>Valdis</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Medicine, University of Latvia, Riga, LVA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furst</LastName><ForeName>Daniel E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Rheumatology, University of California Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology, University of Washington, Seattle, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology, University of Florence, Florence, ITA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">c-reactive protein</Keyword><Keyword MajorTopicYN="N">cytokine interleukin-6</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">neutrophils-lymphocyte ratio</Keyword><Keyword MajorTopicYN="N">sannipata jwara</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. PSG Institute's Institutional Human Ethics Committee issued approval PSG/IHEC/2020/Appr/FB/034. The study is approved in its present form. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: The clinical study was done jointly funded by AVP Research Foundation, PSG Institute of Medical Sciences and Research, The Arya Vaidya Pharmacy (Coimbatore) Ltd., Kama Ayurveda, Madhuram Narayanan Charitable trust, Vivek Sahni, and OPG Power Generation Private Limited. . Financial relationships: Somit Kumar declare(s) employment and Supplied the trial medications from The Arya Vaidya Pharmacy (Cbe) Ltd. Somit Kumar, Sujith S Eranezhath, Mitravinda S Kakarla declare(s) a grant, employment and stock/stock options from AVP Research Foundation. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39355453</ArticleId><ArticleId IdType="pmc">PMC11444340</ArticleId><ArticleId IdType="doi">10.7759/cureus.68392</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Pal R, Bhadada SK. Diabetes Metab Syndr. 2020;14:513–517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202837</ArticleId><ArticleId IdType="pubmed">32388331</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. Yan Y, Yang Y, Wang F, et al. BMJ Open Diabetes Res Care. 2020;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222577</ArticleId><ArticleId IdType="pubmed">32345579</ArticleId></ArticleIdList></Reference><Reference><Citation>Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Maddaloni E, Buzzetti R. Diabetes Metab Res Rev. 2020;36:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228318</ArticleId><ArticleId IdType="pubmed">32233018</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19: consider cytokine storm syndromes and immunosuppression. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. Lancet. 2020;395:1033–1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Silent hypoxia in COVID-19: pathomechanism and possible management strategy. Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MA, Hosen MJ. Mol Biol Rep. 2021;48:3863–3869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8062941</ArticleId><ArticleId IdType="pubmed">33891272</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomarkers associated with COVID-19 disease progression. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Crit Rev Clin Lab Sci. 2020;57:389–399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7284147</ArticleId><ArticleId IdType="pubmed">32503382</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Proal AD, VanElzakker MB. Front Microbiol. 2021;12:698169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Longitudinal assessment of chest CT findings and pulmonary function after COVID-19 infection. Han X, Chen L, Fan Y, et al. Radiology. 2023;307:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9969419</ArticleId><ArticleId IdType="pubmed">36786698</ArticleId></ArticleIdList></Reference><Reference><Citation>Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G, Winterton D. J Card Fail. 2020;26:470–475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166030</ArticleId><ArticleId IdType="pubmed">32315733</ArticleId></ArticleIdList></Reference><Reference><Citation>The assessment of high sensitivity cardiac troponin in patients with COVID-19: A multicenter study. Perrone MA, Spolaore F, Ammirabile M, Romeo F, Caciagli P, Ceriotti F, Bernardini S. Int J Cardiol Heart Vasc. 2021;32:100715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7796671</ArticleId><ArticleId IdType="pubmed">33457490</ArticleId></ArticleIdList></Reference><Reference><Citation>Remdesivir for the treatment of Covid-19 - final report. Beigel JH, Tomashek KM, Dodd LE, et al. N Engl J Med. 2020;383:1813–1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. J Biol Chem. 2020;295:6785–6797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242698</ArticleId><ArticleId IdType="pubmed">32284326</ArticleId></ArticleIdList></Reference><Reference><Citation>Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Pruijssers AJ, George AS, Schäfer A, et al. Cell Rep. 2020;32:107940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340027</ArticleId><ArticleId IdType="pubmed">32668216</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Charan J, Kaur RJ, Bhardwaj P, Haque M, Sharma P, Misra S, Godman B. Expert Rev Clin Pharmacol. 2021;14:95–103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7784780</ArticleId><ArticleId IdType="pubmed">33252992</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexamethasone in hospitalized patients with Covid-19. Horby P, Lim WS, Emberson JR, et al. N Engl J Med. 2021;384:693–704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis. Hong S, Wang H, Zhang Z, Qiao L. Steroids. 2022;183:109022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8956351</ArticleId><ArticleId IdType="pubmed">35346661</ArticleId></ArticleIdList></Reference><Reference><Citation>Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2023;401:1499–1507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10156147</ArticleId><ArticleId IdType="pubmed">37060915</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Liu J, Pan X, Zhang S, et al. Lancet Reg Health West Pac. 2023;33:100694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9899586</ArticleId><ArticleId IdType="pubmed">36777445</ArticleId></ArticleIdList></Reference><Reference><Citation>Effective treatment of severe COVID-19 patients with tocilizumab. Xu X, Han M, Li T, et al. Proc Natl Acad Sci U S A. 2020;117:10970–10975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245089</ArticleId><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis. Deng J, Heybati K, Ramaraju HB, Zhou F, Rayner D, Heybati S. Infection. 2023;51:21–35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016212</ArticleId><ArticleId IdType="pubmed">35438413</ArticleId></ArticleIdList></Reference><Reference><Citation>Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial. Chopra A, Tillu G, Chuadhary K, et al. PLoS One. 2023;18:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10019690</ArticleId><ArticleId IdType="pubmed">36928877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayurvedic clinical profile of COVID-19 - A preliminary report. Puthiyedath R, Kataria S, Payyappallimana U, et al. J Ayurveda Integr Med. 2022;13:100326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290222</ArticleId><ArticleId IdType="pubmed">32624376</ArticleId></ArticleIdList></Reference><Reference><Citation>A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India. Sankhe AP, Memane NS, Gawali VP, et al. Complement Ther Med. 2022;67:102824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8949691</ArticleId><ArticleId IdType="pubmed">35341943</ArticleId></ArticleIdList></Reference><Reference><Citation>A prospective clinical study of an Ayurveda regimen in COVID 19 patients. Wanjarkhedkar P, Sarade G, Purandare B, Kelkar D. J Ayurveda Integr Med. 2022;13:100365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7572087</ArticleId><ArticleId IdType="pubmed">33100779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayurvedic management through telemedicine of covid hypoxia non-dependent of oxygen support in a patient with chest CT score of 18/25- A case report. A S, G M. J Ayurveda Integr Med. 2022;13:100660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9723920</ArticleId><ArticleId IdType="pubmed">36473403</ArticleId></ArticleIdList></Reference><Reference><Citation>Standalone Ayurvedic treatment of high-risk COVID-19 patients with multiple co-morbidities: A case series. Girija PL, Sivan N, Naik P, Murugavel YA, M Ravindranath T, Cv K. J Ayurveda Integr Med. 2022;13:100466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8277097</ArticleId><ArticleId IdType="pubmed">34276163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayurvedic management of persistent hypoxia in a diabetic and hypertensive COVID-19 patient in the post-hospitalization period-A case report. Joshi J, Naranappa Salethoor S, Kulangara S, Edamala Narayanan PN, Puthiyedath R. J Ayurveda Integr Med. 2022;13:100509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8346329</ArticleId><ArticleId IdType="pubmed">34393459</ArticleId></ArticleIdList></Reference><Reference><Citation>The use of integrative therapy based on Yoga and Ayurveda in the treatment of a high-risk case of COVID-19/SARS-CoV-2 with multiple comorbidities: a case report. Mishra A, Bentur SA, Thakral S, Garg R, Duggal B. J Med Case Rep. 2021;15:95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7903378</ArticleId><ArticleId IdType="pubmed">33627186</ArticleId></ArticleIdList></Reference><Reference><Citation>Multimodal ayurvedic approach in the management of moderate SARS-COV2 infection with co-morbidities - A case report. Mythri HS, Mahto RR. J Family Med Prim Care. 2022;11:344–349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930101</ArticleId><ArticleId IdType="pubmed">35309621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayurvedic management of COVID-19/SARS-CoV-2 along with chronic diabetes mellitus: A case study. Nesari T, Galib R, Dharmarajan P, et al. J Ayurveda. 2021;15:311.</Citation></Reference><Reference><Citation>A case series sharing novel experience of treating viral pandemic cases of morbid, mid aged, mild, moderate &amp; severe grade with only ayurvedic medicines. Patil S. J Ayurveda Integr Med. 2022;13:100420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8136275</ArticleId><ArticleId IdType="pubmed">34024691</ArticleId></ArticleIdList></Reference><Reference><Citation>A prospective, controlled, pilot study of personalised add-on ayurveda treatment in high-risk type II diabetes COVID-19 patients. Kumar S, Eranezhath SS, Vishwanathan VK, et al. Jr Her Med. 2024;43:100836.</Citation></Reference><Reference><Citation>ICMR: Clinical guidance for management of adult covid-19 patients. 2021. https://www.icmr.gov.in/pdf/covid/techdoc/COVID_Clinical_Management_19032023.pdf https://www.icmr.gov.in/pdf/covid/techdoc/COVID_Clinical_Management_19032023.pdf</Citation></Reference><Reference><Citation>Pathophysiology of Covid-19 and host centric approaches in Ayurveda. Pandkar PD, Sachdeva V. J Ayurveda Integr Med. 2022;13:100380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833327</ArticleId><ArticleId IdType="pubmed">33519134</ArticleId></ArticleIdList></Reference><Reference><Citation>Evaluation of traditional ayurvedic Kadha for prevention and management of the novel Coronavirus (SARS-CoV-2) using in silico approach. Maurya DK, Sharma D. J Biomol Struct Dyn. 2022;40:3949–3964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754934</ArticleId><ArticleId IdType="pubmed">33251972</ArticleId></ArticleIdList></Reference><Reference><Citation>Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study. Shree P, Mishra P, Selvaraj C, Singh SK, Chaube R, Garg N, Tripathi YB. J Biomol Struct Dyn. 2022;40:190–203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484581</ArticleId><ArticleId IdType="pubmed">32851919</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophils and COVID-19: Active participants and rational therapeutic targets. Hazeldine J, Lord JM. Front Immunol. 2021;12:680134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206563</ArticleId><ArticleId IdType="pubmed">34149717</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophils in COVID-19. Reusch N, De Domenico E, Bonaguro L, Schulte-Schrepping J, Baßler K, Schultze JL, Aschenbrenner AC. Front Immunol. 2021;12:652470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027077</ArticleId><ArticleId IdType="pubmed">33841435</ArticleId></ArticleIdList></Reference><Reference><Citation>Understanding the role of neutrophils in acute respiratory distress syndrome. Yang SC, Tsai YF, Pan YL, Hwang TL. Biomed J. 2021;44:439–446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481802</ArticleId><ArticleId IdType="pubmed">33087299</ArticleId></ArticleIdList></Reference><Reference><Citation>Modulation of neutrophil (dys)function by Ayurvedic herbs and its potential influence on SARS-CoV-2 infection. Joshi MB, Kamath A, Nair AS, Yedehali Thimmappa P, Sriranjini SJ, Gangadharan GG, Satyamoorthy K. J Ayurveda Integr Med. 2022;13:100424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962552</ArticleId><ArticleId IdType="pubmed">33746457</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflammation and thrombosis: the clot thickens. Libby P, Simon DI. Circulation. 2001;103:1718–1720.</Citation><ArticleIdList><ArticleId IdType="pubmed">11282900</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Lim S, Bae JH, Kwon HS, Nauck MA. Nat Rev Endocrinol. 2021;17:11–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7664589</ArticleId><ArticleId IdType="pubmed">33188364</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Huang C, Wang Y, Li X, et al. Lancet. 2020;395:497–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, et al. Int Immunopharmacol. 2020;89:107088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574843</ArticleId><ArticleId IdType="pubmed">33129099</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study. Soliman AT, Prabhakaran Nair A, Al Masalamani MS, et al. Acta Biomed. 2020;91:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716959</ArticleId><ArticleId IdType="pubmed">32921708</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial. Xiong WZ, Wang G, Du J, Ai W. Integr Med Res. 2020;9:100489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7452296</ArticleId><ArticleId IdType="pubmed">32874913</ArticleId></ArticleIdList></Reference><Reference><Citation>Therapeutic effects of herbal-medicine combined therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Chien TJ, Liu CY, Chang YI, Fang CJ, Pai JH, Wu YX, Chen SW. Front Pharmacol. 2022;13:950012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9475194</ArticleId><ArticleId IdType="pubmed">36120361</ArticleId></ArticleIdList></Reference><Reference><Citation>Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes. Alzaid F, Julla JB, Diedisheim M, et al. EMBO Mol Med. 2020;12:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7461002</ArticleId><ArticleId IdType="pubmed">32816392</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophil-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios: prognostic significance in COVID-19. Bg S, Gosavi S, Ananda Rao A, et al. Cureus. 2021;13:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875321</ArticleId><ArticleId IdType="pubmed">33585111</ArticleId></ArticleIdList></Reference><Reference><Citation>Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19. Moin AS, Sathyapalan T, Diboun I, Atkin SL, Butler AE. Sci Rep. 2021;11:6428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7979696</ArticleId><ArticleId IdType="pubmed">33742062</ArticleId></ArticleIdList></Reference><Reference><Citation>Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection. Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Cytometry A. 2020;97:887–890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404377</ArticleId><ArticleId IdType="pubmed">32654350</ArticleId></ArticleIdList></Reference><Reference><Citation>Can monocytopenia be a new indicator in determining survival in covid-19 disease? Pehlivan O, Serin SO, Yesil EE, Demirdag F. Clin Lab. 2021;67</Citation><ArticleIdList><ArticleId IdType="pubmed">34655211</ArticleId></ArticleIdList></Reference><Reference><Citation>In-vivo immunomodulatory activity of standardized Stereospermum suaveolens (Roxb.) DC. root extract. Maji AK, Samanta SK, Mahapatra S, Banerji P, Banerjee D. Orient Pharm Exp Med. 2014;14:47–54.</Citation></Reference><Reference><Citation>Ayurveda Rasayana as antivirals and immunomodulators: potential applications in COVID-19. Singh R, Goel S, Bourgeade P, Aleya L, Tewari D. Environ Sci Pollut Res Int. 2021;28:55925–55951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422837</ArticleId><ArticleId IdType="pubmed">34491498</ArticleId></ArticleIdList></Reference><Reference><Citation>Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals. Rajamanickam A, Kumar NP, Pandiarajan AN, et al. Sci Rep. 2021;11:20254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8511073</ArticleId><ArticleId IdType="pubmed">34642411</ArticleId></ArticleIdList></Reference><Reference><Citation>FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Junqueira C, Crespo Â, Ranjbar S, et al. Nature. 2022;606:576–584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Platelets and COVID-19. Rohlfing AK, Rath D, Geisler T, Gawaz M. Hamostaseologie. 2021;41:379–385.</Citation><ArticleIdList><ArticleId IdType="pubmed">34695854</ArticleId></ArticleIdList></Reference><Reference><Citation>The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants. Jiang SQ, Huang QF, Xie WM, Lv C, Quan XQ. Br J Haematol. 2020;190:0–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">32420607</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanism of thrombocytopenia in COVID-19 patients. Xu P, Zhou Q, Xu J. Ann Hematol. 2020;99:1205–1208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156897</ArticleId><ArticleId IdType="pubmed">32296910</ArticleId></ArticleIdList></Reference><Reference><Citation>The COVID complex: a review of platelet activation and immune complexes in COVID-19. Jevtic SD, Nazy I. Front Immunol. 2022;13:807934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8965558</ArticleId><ArticleId IdType="pubmed">35371058</ArticleId></ArticleIdList></Reference><Reference><Citation>Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. Qu R, Ling Y, Zhang YH, et al. J Med Virol. 2020;92:1533–1541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228291</ArticleId><ArticleId IdType="pubmed">32181903</ArticleId></ArticleIdList></Reference><Reference><Citation>The impact of COVID-19 disease on platelets and coagulation. Wool GD, Miller JL. Pathobiology. 2021;88:15–27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7649697</ArticleId><ArticleId IdType="pubmed">33049751</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Amgalan A, Othman M. Platelets. 2020;31:740–745.</Citation><ArticleIdList><ArticleId IdType="pubmed">32456506</ArticleId></ArticleIdList></Reference><Reference><Citation>Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Banerjee A, Pasea L, Harris S, et al. Lancet. 2020;395:1715–1725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217641</ArticleId><ArticleId IdType="pubmed">32405103</ArticleId></ArticleIdList></Reference><Reference><Citation>Persistent cardiac injury - An important component of long COVID-19 syndrome. Chidambaram V, Kumar A, Calcaterra G, Mehta JL. EBioMedicine. 2022;77:103892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8864184</ArticleId><ArticleId IdType="pubmed">35219086</ArticleId></ArticleIdList></Reference><Reference><Citation>CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation. Prokop M, van Everdingen W, van Rees Vellinga T, et al. Radiology. 2020;296:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233402</ArticleId><ArticleId IdType="pubmed">32339082</ArticleId></ArticleIdList></Reference><Reference><Citation>Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Han X, Fan Y, Alwalid O, et al. Radiology. 2021;299:0–86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19) Pan F, Ye T, Sun P, et al. Radiology. 2020;295:715–721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233367</ArticleId><ArticleId IdType="pubmed">32053470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest CT patterns from diagnosis to 1 year of follow-up in patients with COVID-19. Pan F, Yang L, Liang B, et al. Radiology. 2022;302:709–719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515211</ArticleId><ArticleId IdType="pubmed">34609153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>